Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-5: Fondaparinux vs Enoxaparin in UA/NSTEMI
NCT00139815Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2003
- Primary completion
- Dec 2005
- Modality
- Allosteric Modulators
01
Overview
Phase 3, randomised, double-blind trial of fondaparinux in unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI), sponsored by GSK. Primary endpoint: Composite of Death, Myocardial Infarction, or Refractory Ischemia at 9 days. Started Apr 2003; status: completed.
02
Drugs
fondaparinux
03
Conditions
unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT00139815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139815.